Clinical trials: Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as…
- Trial name
- BTX-A-HAC NG (NCT02353871)
- Testing
- Botulinum toxin type A
- Where
- 9 sites in France, Germany
- Volunteers
- 185 people
- Sponsor
- Ipsen
Glabellar Lines, Lateral Canthal Lines
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
- Trial name
- READY-4 (NCT04225260)
- Testing
- botulinum toxin neuromodulator
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines, Wrinkles
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1.
- Trial name
- NCT02718118
- Testing
- Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to…
- Trial name
- NCT05100199
- Testing
- OnabotulinumtoxinA X
- Where
- 18 sites in United States
- Volunteers
- 328 people
- Sponsor
- Allergan
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770211
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States
- Volunteers
- 271 people
- Sponsor
- Merz Pharmaceuticals GmbH
Moderate to Severe Glabellar Frown Lines
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
- Trial name
- NCT03806933
- Testing
- NT 201
- Where
- 9 sites in United States, Germany
- Volunteers
- 241 people
- Sponsor
- Merz Aesthetics GmbH
Glabellar Frown Lines
Treatment of Moderate to Severe Glabellar Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
- Trial name
- READY-1 (NCT04249583)
- Testing
- botulinum toxin
- Where
- 14 sites in United States, Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of…
- Trial name
- NCT02493946
- Testing
- Botulinum toxin type A
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 600 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines…
- Trial name
- NCT01485601
- Testing
- MT10109
- Where
- Australia
- Volunteers
- 121 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
- Trial name
- NCT03004248
- Testing
- Botulinum Toxins, Type A
- Where
- 61 sites in United States, Canada
- Volunteers
- 2,691 people
- Sponsor
- Revance Therapeutics, Inc.
Skin Aging
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)
- Trial name
- NCT00856414
- Testing
- botulinum toxin Type A
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Rhytides
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.
- Trial name
- NCT01814670
- Testing
- botulinum toxin Type A
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Allergan
Glabellar Frown Lines
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.
- Trial name
- NCT01391312
- Testing
- botulinum toxin Type A
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.